1. Aldoss IT, Weisenburger DD, Fu K, et al: Adult Burkitt lymphoma: Advances in diagnosis and treatment. Oncology (Williston Park) 22:1508-1517, 2008.
2. Dave SS, Fu K, Wright GW, et al: Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354:2431-2442, 2006.
3. Hummel M, Bentink S, Berger H, et al: A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006.
4. Swerdlow SH, Campo E, Harris NL, et al (eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva, Switzerland; WHO Press; 2008.
5. Hoelzer D: Recent results in he treatment of Burkitt lymphomas (abstract 008). Ann Oncol 19(suppl 4):iv83, 2008.
6. Dunleavy K, Little RF, Pittaluga S, et al: A prospective study of dose-adjusted (DA) EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: A regimen with high efficacy and low toxicity (abstract 009). Ann Oncol 19(suppl 4):iv83, 2008.
7. Friedberg JW, Ciminello L, Kelly J, et al: Outcome of patients > age 40 years with Burkitt lymphoma (BL) treated with aggressive chemotherapeutic regimens: Results from the International Burkitt Lymphoma Collaborative Group (abstract 928). Blood 106(11):273a, 2005.
8. Seam P, Juweid ME, Cheson BD: The role of FDG-PET scans in patients with lymphoma. Blood 110:3507-3516, 2007.
